Frank Sciurba

Stories

AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials

As of September 2026: Led the OBERON and TITANIA Phase III trials

Millions of COPD patients who don't respond to current biologic treatments may soon have a new option. AstraZeneca's tozorakimab cut moderate-to-severe flare-ups by 29% to 34% in two late-stage trials, and unlike existing biologics, it worked across all blood eosinophil levels.

Updated Sep 10

Notable Quotes

The OBERON and TITANIA trials mark the first time we have seen a biologic in COPD achieve efficacy in a broad population across blood eosinophil thresholds, including in patients with baseline eosinophils below 150, and irrespective of smoking status.

from AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials · Updated Sep 10

It is encouraging to have an additional, safe therapy for patients who often struggle to breathe.

from AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials · Updated Sep 10